# DESCRIPTION

## TECHNICAL FIELD

- introduce JAK1 modulators for CLE and LP treatment

## BACKGROUND

- define cutaneous lupus erythematosus
- describe interface dermatitis
- discuss multifactorial origin of CLE
- explain UV radiation's role in CLE
- describe cell debris clearance impairment
- discuss TREX1 gene mutations
- explain DAMPs and type I IFN production
- describe JAK/STAT pathway and proinflammatory mediators
- discuss limitations of current CLE treatment options

## SUMMARY

- summarize JAK1 selective inhibitor administration for CLE and LP treatment

## DETAILED DESCRIPTION

- introduce disease treatment method
- specify disease types
- define cutaneous lupus
- explain CLASI scoring system
- categorize cutaneous lupus subtypes
- describe acute cutaneous lupus erythematosus
- detail malar rash characteristics
- explain chronic cutaneous lupus subtypes
- describe discoid lupus erythematosus
- detail histologic examination of DLE
- describe lupus erythematosus profundus
- detail histology of LEP
- describe chilblain lupus
- detail pathology of CHLE
- describe lupus tumidus
- explain subacute cutaneous lupus
- discuss role of type I IFNs in lupus erythematosus
- summarize previous therapeutic strategies
- introduce JAK family
- describe JAK inhibitors
- discuss JAK inhibitors in CLE and associated skin disorders
- describe baricitinib trial for SLE
- discuss CLASI scoring system
- introduce JAK1 inhibitors
- list JAK1 inhibitor compounds
- describe JAK1 selective inhibitors
- discuss JAK1 inhibition in autoimmune diseases and cancers
- describe JAK1 inhibitor selectivity over JAK2
- introduce Table 1
- describe compounds in Table 1
- introduce {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin
- describe {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin
- introduce adipic acid salt
- describe synthesis and preparation of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]
- reference US Patent Publ. No. 2011/0224190
- reference US Patent Publ. No. 2013/0060026
- reference US Patent Publ. No. 2014/0256941
- discuss JAK1 inhibition in rheumatoid arthritis
- discuss IL-6 signaling through JAK1
- discuss potential clinical benefit of JAK1 inhibition
- conclude JAK1 inhibition
- define JAK1 inhibitors
- specify JAK1 inhibitor structures
- provide synthesis methods
- reference prior art
- describe JAK1 inhibitor salts
- specify JAK1 inhibitor compounds
- provide synthetic procedures
- describe JAK1 inhibitor formulas
- specify JAK1 inhibitor compounds of Formula I
- specify JAK1 inhibitor compounds of Formula II
- define R4-R11
- describe compound of Formula II
- describe JAK1 inhibitor of Formula III
- describe Cy4 and R12
- describe compound of Formula III embodiment
- describe method of treating cutaneous lupus erythematosus
- describe method of treating cutaneous lichen planus
- describe ruxolitinib phosphate
- describe topical formulation
- describe administering frequency
- describe isotopic substitution
- describe synthetic methods for isotopic labeling
- describe therapeutic advantages of isotopic substitution
- describe JAK1 inhibitor with deuterium atoms
- define "optionally substituted"
- define "substituted"
- define "n-m alkyl"
- define "alkylene"
- define "HO—C1-3-alkyl"
- define "CN—C1-3 alkyl"
- define "amino"
- define "di(C1-3-alkyl)amino"
- define "C1-3 alkylamino"
- define "di(C1-3 alkyl)aminosulfonyl"
- define "C1-3 alkylsulfonyl"
- define "halo"
- define "Cn-m haloalkyl"
- define "C1-3 fluoroalkyl"
- define "C3-6 cycloalkyl"
- define "C3-6 cycloalkyl-C1-3 alkyl"
- describe stereoisomers
- describe resolution of racemic mixtures

### Combination Therapies

- describe combination therapies
- administer additional therapeutic agents
- specify antibiotic options
- detail retinoid options
- describe steroid options
- specify anti-TNF-alpha agent options
- describe immunosuppressant options
- list additional therapeutic agents
- describe BRM options
- specify hypomethylating agent options
- describe IMiD options
- list additional therapeutic agents
- describe JAK inhibitor options
- specify JAK1/JAK2 inhibitor options
- describe ruxolitinib
- describe baricitinib
- describe isotopically-labeled compounds
- specify JAK1/JAK2 inhibitor compounds
- describe compounds of Formula IV
- list JAK1/JAK2 inhibitor compounds
- describe additional JAK inhibitor options
- specify additional therapeutic agents
- describe Bcr-Abl inhibitor options
- describe Flt-3 inhibitor options
- describe RAF inhibitor options
- describe FAK inhibitor options
- describe combination therapy with kinase inhibitors
- list additional therapeutic agents

### Pharmaceutical Formulations and Dosage Forms

- introduce pharmaceutical compositions
- describe administration routes
- detail topical administration
- list pharmaceutical carriers
- describe topical formulations
- introduce pH-adjusting agents
- introduce chelating agents
- introduce preservatives
- introduce co-solvents
- introduce penetration enhancers
- introduce thickening agents
- introduce gelling agents
- introduce viscosity building agents
- introduce surfactants
- introduce propellants
- introduce fragrance
- introduce colorants
- describe oral administration
- describe parenteral administration
- introduce pharmaceutical excipients
- describe milling procedures
- introduce nanoparticulate preparations
- list suitable excipients
- introduce lubricating agents
- introduce wetting agents
- introduce emulsifying agents
- introduce suspending agents
- introduce preserving agents
- introduce sweetening agents
- introduce flavoring agents
- describe sustained release compositions
- introduce silicified microcrystalline cellulose
- describe wet granulation process
- describe dry granulation process
- introduce unit dosage forms
- describe dosage ranges
- introduce pharmaceutical vehicles
- describe nebulized solutions
- introduce topical dosage forms
- describe advantages of topical administration
- introduce conventional carriers
- describe ointment compositions
- describe cream compositions
- describe gel compositions
- introduce packaging instructions
- describe therapeutic dosages

### Kits

- introduce pharmaceutical kits

## EXAMPLES

- provide examples of the invention

### Example 1. In Vitro JAK Kinase Assay

- describe JAK1 inhibitors assay
- measure IC50 values of compounds

### Example 2. Activated JAK1 is Strongly Expressed in Human CLE Skin Lesions

- investigate JAK1-mediated signaling in CLE
- analyze pJAK1 expression in lesional skin

### Example 2. JAK/STAT-Associated Innate Inflammatory Pathways are Significantly Activated in Human CLE Skin

- analyze gene expression in CLE skin lesions
- identify activated JAK/STAT pathways
- show increased expression of proinflammatory genes

### Example 3. INCB039110 Significantly Inhibits JAK1-Phosphorylation in Cultured Immortalized Human Keratinocytes

- analyze functional principle of JAK inhibition
- stimulate keratinocytes with endogenous nucleic acids
- show inhibition of JAK1-phosphorylation by INCB039110

### Example 4. Pharmacological JAK1 Inhibition Blocks the Expression of CLE-Typical Proinflammatory Cytokines and Pathway Molecules in Vitro

- investigate efficacy of pharmacological JAK1 inhibition
- analyze gene expression in CLE models
- show downregulation of proinflammatory genes

### Example 5. In Vivo Topical Application of INCB039110 Ameliorates CLE-Like Lesions in Lupus-Prone TREX1−/− Mice

- treat TREX1−/− mice with INCB039110
- show improvement of CLE-like lesions

### Example 6. In Vivo Topical Application of INCB054707 Ameliorates CLE-Like Lesions in Lupus-Prone MRL-Lpr Mice

- treat MRL-lpr mice with INCB054707
- show improvement of CLE-like lesions
- analyze dose-dependent effects

